Helix BioMedix is a biotechnology company dedicated to the development and commercialization of next-generation protein scaffold technologies for tissue repair and hemostasis. Founded in the early 2000s and headquartered in McPherson, Kansas, the company applies proprietary protein-based platforms to create bioresorbable devices designed to support the body’s natural healing processes. Helix BioMedix focuses on areas such as orthopedic and spinal surgery, wound management, and cardiovascular repair, leveraging advanced biomaterial science to deliver targeted therapeutic solutions.
The company’s core product line centers on a range of bioresorbable hemostatic agents and extracellular matrix scaffolds. One flagship offering is a malleable bone hemostat designed to control bleeding in complex surgical sites, which gradually dissolves as new tissue forms. In parallel, Helix BioMedix has advanced a family of injectable microbead scaffolds intended for minimally invasive delivery in cardiovascular and soft tissue applications. These devices are engineered to provide structural support, promote cell adhesion, and accelerate tissue regeneration without the need for additional surgical removal.
Helix BioMedix maintains a network of collaboration with academic medical centers, surgical device distributors, and contract research organizations to drive clinical evaluation and regulatory approval. While its primary market remains the United States, the company has initiated partnerships in Europe and select Asia-Pacific countries to broaden adoption of its scaffold technologies. Distribution agreements are being pursued to integrate Helix BioMedix devices into existing surgical instrumentation platforms and enhance global availability.
Under the leadership of CEO Joel Kline, Helix BioMedix’s management team combines expertise in biomaterials engineering, regulatory affairs, and commercial strategy. The board of directors includes seasoned industry veterans and scientific advisors who guide product development and clinical programs. As the company continues to advance its pipeline, Helix BioMedix is positioned to address unmet clinical needs in tissue repair by delivering innovative, protein-based implant solutions that support improved patient outcomes.
AI Generated. May Contain Errors.
Free HXBM Stock Alerts